NCT04809012

Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors

An Open-label, Multicenter, Phase 2 Basket Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Sorrento Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study evaluates the efficacy of STI-3031, an anti-PD-L1 antibody, in previously treated patients with selected solid tumors.

Detailed description

This is an open-label, multicenter, Phase 2 basket study to investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of STI-3031, an anti-PD-L1 antibody, in patients with selected RRSTs. All participants will receive STI-3031 20 mg/kg every 2 weeks (Q2W) via IV infusion over approximately 60 minutes.

Conditions

• Solid Tumor
• Refractory Tumor
• Relapsed Solid Tumor

Interventions

Type	Name	Description
BIOLOGICAL	STI-3031	STI-3031 is an anti-PD-L1 antibody

Timeline

• Start date: 2021-06-01
• Primary completion: 2024-06-01
• Completion: 2024-06-01
• First posted: 2021-03-22
• Last updated: 2022-03-25

Regulatory

• FDA-regulated drug study